Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DHG Pharmaceutical JSCSTC:DHG +0.84%80 EBITDA Margin % is 28.48% as of Jun. 2026, which is 26% above its 10-year median of 22.66. GuruFocus rates STC:DHG with a GF Score™ of 80/100 and a GF Value™ of ₫113,347.30 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 960 Drug Manufacturers companies, DHG Pharmaceutical JSC ranks better than 76.77% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
DHG Pharmaceutical JSC EBITDA Margin % Related Terms
DHG Pharmaceutical JSC EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for DHG Pharmaceutical JSC's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DHG Pharmaceutical JSC's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DHG Pharmaceutical JSC EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DHG Pharmaceutical JSC's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where DHG Pharmaceutical JSC's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHG Pharmaceutical JSC (STC:DHG) has a EBITDA Margin % of 28.48% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DHG Pharmaceutical JSC and its competitors. This is 26% above median its historical median of 22.66. Over the past decade, DHG Pharmaceutical JSC's EBITDA Margin % has ranged from 20.57 to 25.52. According to the industry distribution chart, DHG Pharmaceutical JSC ranks #223 out of 960 companies in the Drug Manufacturers industry, placing it in the top 23.2%.
Is DHG Pharmaceutical JSC's EBITDA Margin % too high?
DHG Pharmaceutical JSC's current EBITDA Margin % of 28.48% is 26% above median its 10-year median of 22.66. Over the past 10 years, this metric has ranged from a low of 20.57 to a high of 25.52. The Drug Manufacturers industry median EBITDA Margin % is 12.16. DHG Pharmaceutical JSC's value of 28.48% is 134.3% above this industry median. Based on the distribution chart, DHG Pharmaceutical JSC ranks #223 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, DHG Pharmaceutical JSC has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DHG Pharmaceutical JSC's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, DHG Pharmaceutical JSC ranks #223 out of 960 companies for EBITDA Margin %. This places DHG Pharmaceutical JSC in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.16. DHG Pharmaceutical JSC's value of 28.48% is 134.3% above this benchmark. Historically, DHG Pharmaceutical JSC's own EBITDA Margin % has ranged from 20.57 to 25.52 over the past decade. While the company's 10-year median is 22.66 vs. the industry median of 12.16, DHG Pharmaceutical JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.16, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DHG Pharmaceutical JSC's current EBITDA Margin % of 28.48% is 134.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DHG Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DHG Pharmaceutical JSC's current EBITDA Margin % is 28.48%, which is 26% above median its own 10-year median of 22.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DHG Pharmaceutical JSC stock overvalued right now?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC (STC:DHG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫113,347.30, compared to a current price of ₫95,600.00 — trading 15.7% below its estimated fair value. The current EBITDA Margin % is 28.48%, which is 26% above median its 10-year median of 22.66 and 134.3% above the Drug Manufacturers industry median of 12.16. DHG Pharmaceutical JSC's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For DHG Pharmaceutical JSC (STC:DHG), the current EBITDA Margin % is 28.48% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DHG Pharmaceutical JSC (STC:DHG) Overvalued in 2026?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC stock appears to be undervalued.
The current stock price of ₫95,600.00 is trading 15.7% below its estimated GF Value™ of ₫113,347.30.
GuruFocus considers DHG Pharmaceutical JSC to be Modestly Undervalued.
Key valuation signals for STC:DHG:
EBITDA Margin %: 28.48% (26% above median its 10-year median of 22.66)
GF Value™: ₫113,347.30 vs. price of ₫95,600.00 (15.7% below fair value)
Industry Position: 134.3% above the Drug Manufacturers median (#223 of 960)
No single metric tells the full story. See the STC:DHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotics, antifungals, and antiparasitics; analgesics and antipyretics; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.
80GF Score
Get the complete analysis for STC:DHG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DHG has been successfully added to your 
